Navigation Links
ViroPharma To Acquire Lev Pharmaceuticals
Date:7/15/2008

nt activities in diseases including cytomegalovirus (CMV) and C. difficile. For more information on ViroPharma, visit the company's website at http://www.viropharma.com.

About Lev Pharmaceuticals, Inc.

Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Lev's lead product candidate, Cinryze(TM) (C1 inhibitor (human)), is being developed as a replacement therapy for hereditary angioedema (HAE), also known as C1 inhibitor deficiency. Additionally, Lev is in the process of prioritizing its C1 inhibitor development platform for the treatment of selective other diseases and disorders in which inflammation is known or believed to play an underlying role.

ViroPharma Forward-Looking Statements

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. Such forward-looking statements include, but are not limited to, statements about the benefits of the business combination transaction involving ViroPharma and Lev, including, among others, future financial and operating results, cost savings, enhanced revenues, ViroPharma's plans, objectives, expectations and intentions and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the ability to obtain regulatory approvals of the transaction on the proposed terms and schedule; the failure of Lev stockholders to approve the transaction; the risk that the businesses will not be integrated successfully; the risk that the cost savings and any other synergies from the transaction may not be fully realized or may take longer to realize than expected; the risk that revenues following the merger will be lower than expected; disruption from the transaction making it more diffi
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. ViroPharma to Present at Two Upcoming Healthcare Conferences
2. ViroPharma Provides 2008 Outlook
3. ViroPharma to Present at the BIO CEO & Investor Conference
4. ViroPharma to Release 2007 Fourth Quarter and Full Year Financial Results on February 27, 2008
5. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
6. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
7. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
8. ViroPharma to Present at Two Upcoming Healthcare Conferences
9. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
10. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
11. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 Research ... addition of the "International Photonic Integrated Circuit ... Forecasts to 2019" report to their offering. ... The concept of photonic integration traces its ... century. The promise of photonic integration went unexplored ...
(Date:7/10/2014)... WASHINGTON D.C., April 15, 2014 -- According to ... danger to nuclear security comes from terrorists acquiring ... (HEU) to construct a crude nuclear explosive device. ... illicit nuclear trafficking have involved gram-level quantities, which ... methods. , According to a new study appearing ...
(Date:7/10/2014)... 17, 2014 Using microscopic polymer light resonators ... researchers at MIT,s Quantum Photonics Laboratory have developed ... the parts-per-billion range. Optical sensors are ideal for ... signal-to-noise ratio, compact, lightweight nature, and immunity to ... had been developed before, the MIT team conceived ...
(Date:7/10/2014)... basis of psychiatric disorders has been extremely challenging because ... but are insufficient to cause disease. Now investigators reporting ... journal Cell Stem Cell describe a strategy ... interact with other risk factors or environmental exposures to ... pinpoints a genetic variant that may predispose individuals to ...
Breaking Biology Technology:International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Sensitive detection method may help impede illicit nuclear trafficking 2Swell new sensors 2New strategy could uncover genes at the root of psychiatric illnesses 2
... ChemAxon, a software,solutions provider for cheminformatics ... their cheminformatics toolkits, Marvin & JChem. The ... Markush enumeration and,core development in JChem search, ... JChem is a suite of application programming ...
... Feb. 19 NeurogesX, Inc.,(Nasdaq: NGSX ), ... therapies, announced today that it is scheduled to ... Growth Stock Conference in,Laguna Niguel, CA on February ... will be presenting and Stephen Ghiglieri, Chief,Financial Officer, ...
... Proprietary Technology Adopted in 16% of U.S. Cardiology ... ICG Acceptance and Clinical Importance, SAN DIEGO, ... leader of BioZ(R) impedance cardiography (ICG),technology, today announced ... American College of Cardiology,s ACCEL audio series., ...
Cached Biology Technology:ChemAxon Launches Marvin and JChem Version 5: Better User Experience, Better Integration, More Flexibility and Higher Performance 2NeurogesX to Present at Roth 2008 OC Growth Stock Conference 2NeurogesX to Present at Roth 2008 OC Growth Stock Conference 3CardioDynamics BioZ(R) ICG Technology Featured in American College of Cardiology (ACC) Audio Series 2CardioDynamics BioZ(R) ICG Technology Featured in American College of Cardiology (ACC) Audio Series 3
(Date:7/10/2014)... 2014 Smart technology emphasis grows in ... improved security: NXT-ID, Inc. (OTCBB: NXTD), eBay Inc. (NASDAQ: ... Apple Inc. (NASDAQ: AAPL ), Visa Inc. (NYSE: ... NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused on ... second series of 30 second spots on CNBC for its ...
(Date:7/10/2014)... NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused on ... Pereira was interviewed on July 1 st on ... . Mr. Pereira discusses the company,s next generation smart ... how the Wocket™ aims to replace a traditional wallet with ... Harris tells Gino he has never heard of the ...
(Date:7/10/2014)... Sweden , July 7, 2014 ... its first major design win (DW). A Chinese Top 5 ... the planned start of mass production in October 2014.   ... a Chinese Top 5 smartphone OEM, which has a planned ... and a target sales volume for this phone of 3 ...
Breaking Biology News(10 mins):Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2
... report discovering the receptor through which a group of life-threatening ... show that infection can be inhibited by blocking this receptor. ... on February 7, give a clue to the high lethality ... severity of infection, and point the way toward a sorely ...
... in the 1960s, the industry has continued to rapidly grow ... for farmed salmon have plummeted and, there is concern that ... "Farmed fish escaping from marine net pens might become an ... fish biologist Peter Bisson. "Net pen culture of salmon is ...
... in the January 3 issue of the Journal ... of hereditary retinoblastoma survivors developing specific subtypes of soft ... decades after the original retinoblastoma diagnosis. The findings emphasize ... the authors say. , Retinoblastoma is a rare ...
Cached Biology News:Discovery could lead to better control of hemorrhagic fever viruses 2Discovery could lead to better control of hemorrhagic fever viruses 3Farmed salmon could become an invasive species in forest streams 2Study examines risk of soft tissue sarcomas in hereditary retinoblastoma survivors 2